- The placement of new Focal Ones got off to a good start this year and a filled-up pipeline is promising more, boosted by a big reimbursement improvement for Medicare.
- Reimbursement for Medicare patients’ procedures almost doubled in July, significantly improving the economics for the Focal One.
- This should also speed up reimbursement from private payers and boost market acceptance.
- Most revenues still come from an exclusive distribution deal for the ExactVu with Exact Imaging, a clever move tiding the company over until reimbursement is improved.
- Looking for more investing ideas like this one? Get them exclusively at SHU Growth Portfolio. Learn More »
EDAP’s Focal One Revenue Is Set To Accelerate (NASDAQ:EDAP) | Seeking Alpha